Tafamidis
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tafamidis
Tafamidis: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate for Tafamidis with a score of 0.99 or higher, so there is currently no new predicted indication for this drug. The uses recorded for Tafamidis are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| amyloidosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| ah amyloidosis |
| al amyloidosis |
| attrv122i amyloidosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14100D | Vyndamax | Capsule 61 mg | Valid |
Safety Considerations
- Drug Interactions (13 records, from DDInter and pharmacology sources):
- Major: Ozanimod.
- Moderate: Rosuvastatin, deferasirox, eltrombopag, lusutrombopag, artesunate, axitinib, methotrexate, irinotecan (including liposomal), belinostat and imatinib.
- Tafamidis’s pharmacological target is transthyretin (TTR).
For warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.